Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Related news for (PHAT)
- Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
- 24/7 Market News Snapshot 07 August, 2025 – Phathom Pharmaceuticals, Inc. Common Stock (NASDAQ:PHAT)
- Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
- Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
- 24/7 Market News Snapshot 06 June, 2025 – Phathom Pharmaceuticals, Inc. Common Stock (NASDAQ:PHAT)